Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10189850 CDK inhibitors

Patent 10189850 was granted and assigned to G1 Therapeutics on January, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

G1 Therapeutics

Current Assignee

G1 Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

101898500

Patent Inventor Names

Francis X. Tavares0

Jay C. Strum0

Date of Patent

January 29, 2019

Patent Application Number

159188520

Date Filed

March 12, 2018

Patent Citations Received

‌

US Patent 10660896 Transient protection of normal cells during chemotherapy

‌

US Patent 11364222 Combination therapy for treatment of cancer

‌

US Patent 11357779 G1T38 superior dosage regimes

‌

US Patent 10618905 Pyrimidine-based compounds for the treatment of cancer

‌

US Patent 11643416 Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors

Patent Primary Examiner

‌

Jeffrey H Murray

Patent abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10189850 CDK inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API